Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bayesian estimation of cost-effectiveness from censored data.

Daniel F Heitjan1, Clara Yuri Kim, Huiling Li

  • 1Department of Biostatistics & Epidemiology, University of Pennsylvania School of Medicine, 622 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021, U.S.A. dheitjan@cceb.upenn.edu

Statistics in Medicine
|April 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating clinical trial hazard functions.

Clinical trials (London, England)·2026
Same author

A Note on the Complementary Mixture Pareto II Distribution.

Communications in statistics: theory and methods·2026
Same author

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes.

Frontiers in cardiovascular medicine·2025
Same author

Role of Harmaline in Inhibiting c-Myc, Altering Molecular Typing, and Promoting Apoptosis in Triple-Negative Breast Cancer.

Breast cancer (Dove Medical Press)·2024
Same author

The highly hazardous veterinary drug "maduramicin" and its toxicokinetics in rats.

Heliyon·2024
Same author

PVA-enhanced green synthesis of CMC-based lithium adsorption films.

Carbohydrate polymers·2024

This study introduces a Bayesian method to assess new treatment cost-effectiveness in clinical trials. It handles censored survival and cost data, aiding healthcare economic evaluations.

Area of Science:

  • Biostatistics
  • Health Economics
  • Clinical Trials

Background:

  • Estimating treatment cost-effectiveness is crucial for healthcare decisions.
  • Censoring in survival data complicates cost-effectiveness analysis.
  • Standard methods may not adequately address censored cost and survival data.

Purpose of the Study:

  • To develop and illustrate a Bayesian methodology for cost-effectiveness analysis in clinical trials.
  • To account for the induced censoring of total cost due to survival censoring.
  • To provide a robust statistical framework for comparing new versus standard treatments.

Main Methods:

  • A Bayesian statistical model was employed.
  • Survival data were modeled using a Weibull distribution.

Related Experiment Videos

  • Total health care cost was modeled using a gamma distribution with a mean dependent on survival time.
  • Importance sampling was used to summarize posterior distributions.

    • Main Results:

    • The methodology effectively estimates cost-effectiveness under censoring.
    • The analysis demonstrated the practical application of the Bayesian approach.
    • Key parameters' posterior distributions were successfully summarized.

    Conclusions:

    • The proposed Bayesian methodology provides a sound approach for cost-effectiveness estimation in the presence of censored data.
    • This method enhances the evaluation of new treatments in randomized clinical trials.
    • The findings support the use of advanced statistical modeling in health economic assessments.